Showing results for:
Vidaza® is FDA approved to treatAdult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1.1) Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).
Vidaza® Azacitidine Onureg®
Bortezomib is FDA approved to treat people with myeloma and for the retreatment of adult patients with myeloma who had previously responded to bortezomib therapy and relapsed at least six months following completion of prior bortezomib treatment. Bortezomib is also approved to treat people with previously untreated mantle cell lymphoma as well as patients who have received at least one prior therapy.
Velcade® Bortezomib
Daunorubicin and cytarabine is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Vyxeos® Daunorubicin and cytarabine
Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.
Etopophos® Toposar® VePesid® VP-16 Etoposide
Mechlorethamine gel is FDA approved for the treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Valchlor® Mechlorethamine gel
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Vonjo™ Pacritinib
Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
Quizartinib Vanflyta®
Teniposide is FDA approved along with other medicines as induction therapy to treat people who have refractory childhood acute lymphoblastic leukemia, non-Hodgkin lymphoma and other types of cancer. This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.
Vumon® VM-26 Teniposide
Tretinoin is an FDA-approved drug that is used to induce remission in patients who have acute promyelocytic leukemia (APL, also known as "M3 AML"), a type of acute myeloid leukemia (AML), with the t(15;17) translocation and/or the presence of the PML-RARa gene and who are intolerant of, refractory to, or have relapsed from anthracycline-based chemotherapy.
Vesanoid® ATRA Tretinoin All-trans retinoic acid (ATRA)
Vemurafenib (Zelboraf®) is FDA approved for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
Zelboraf® Vemurafenib
Venetoclax is FDA approved For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Venclexta® Venetoclax
Vinblastine is an FDA-approved chemotherapy agent that is used to treat people who have acute leukemia. It is sometimes used to treat other types of cancer including lymphoma.
Velban® Vinblastine
Vincristine is an FDA-approved chemotherapy agent that is used to treat some types of blood cancer as well as some noncancerous conditions. Vincristine may cause hair loss in some patients. After treatment with vincristine has ended, or sometimes even during treatment, normal hair growth should return.
Oncovin® Vincristine
Vincristine sulfate liposome injection
Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
Marqibo®
Vincristine sulfate liposome injection
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Zolinza® Vorinostat